Morgan Stanley Maintained Overweight on APEMY (Aperam S.A.) Feb 2026

Morgan Stanley maintained an Overweight rating on Aperam S.A. (APEMY) on February 19, 2026 and raised its price target to EUR 47 from EUR 40. This APEMY analyst rating update signals continued confidence from a major broker and includes a 17.5% uplift in the target. The move accompanied a 1.42% ($0.72) intraday price change.

APEMY analyst rating: Morgan Stanley action and source

On February 19, 2026 at 11:49 AM, Morgan Stanley maintained Overweight on APEMY and lifted the price target to EUR 47 from EUR 40. The report is summarized by TheFly source. The update drove a 1.42% ($0.72) price change the same day.

What the Morgan Stanley call means for investors

A maintained Overweight rating signals Morgan Stanley expects APEMY to outperform peers. Investors should read this as a positive outlook, not a guarantee. The higher price target implies revised earnings or cash flow assumptions from Morgan Stanley that support a richer valuation.

APEMY price target change and valuation context

Raising the target to EUR 47 from EUR 40 equals a 17.5% increase, showing a clearer upside case. With a market cap of $3,722,899,105, the new target changes relative valuation expectations and may widen analyst-implied fair value ranges for Aperam S.A.

Historical analyst coverage and consensus context

Morgan Stanley is a notable broker for European metals names and its maintained Overweight adds weight to current coverage. Recent coverage for Aperam has been selective, and this action keeps Morgan Stanley among the more active houses following the stock.

Trading implications and risk considerations for APEMY

An Overweight rating typically supports higher demand from institutional accounts that follow Morgan Stanley. Investors should weigh commodity price risk and cyclicality in steel and stainless markets. Remember that analyst ratings can change with earnings or macro shifts.

Meyka AI view and next catalysts for APEMY

Meyka AI rates APEMY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Upcoming catalysts to watch include quarterly results, raw material prices, and any updated guidance from Aperam S.A. Meyka AI is an AI-powered market analysis platform tracking real-time analyst moves.

Final Thoughts

Morgan Stanley’s February 19, 2026 maintenance of Overweight for Aperam S.A. and the lift of the price target to EUR 47 signal a more constructive near-term outlook for APEMY analyst rating. The 17.5% target increase and the 1.42% ($0.72) same-day price move show how a single broker note can shift market sentiment. For investors, the maintained Overweight suggests potential relative outperformance, but it is not a guarantee. Weigh this update alongside Aperam’s fundamentals, commodity exposure, and your own risk tolerance. Meyka AI rates APEMY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. For the full analyst note summary see TheFly source and view live price and coverage on our Aperam S.A. profile Meyka APEMY page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.